Company research
TREACE MEDICAL CONCEPTS, INC.
CIK 1630627Updated Sep 26, 2026
SecurityTMCI · NASDAQ · equity
TMCI price & chart
Loading TradingView…
NASDAQ:TMCI on TradingView ↗About the company
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and related deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System - a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for
In the news
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses ↗
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit - TMCI News provided by Levi & Korsinsky, LLP Jun 10, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , June 10, 2025 /PRNewswire/ -- Levi ↗
TMCI Investors Have Final Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Jun 09, 2025, 10:50 ET Share this article Share to X Share this article Share to X LOS ANGELES , June 9, 2025 /PRNewswire/ -- The Schall ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 190,581,000Source | 217,094,000Source | 251,907,000Source | 159,024,000Source |
| Property, Plant and Equipment, NetUSD | 29,752,000Source | 25,953,000Source | 22,298,000Source | 15,338,000Source |
| GoodwillUSD | 12,815,000Source | 12,815,000Source | 12,815,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,125,000Source | 8,075,000Source | 9,025,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,708,000Source | 11,350,000Source | 12,982,000Source | 19,473,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 42,155,000Source | 40,803,000Source | 38,063,000Source | 29,196,000Source |
| Inventory, NetUSD | 36,031,000Source | 39,255,000Source | 29,245,000Source | 19,330,000Source |
| Assets, CurrentUSD | 132,054,000Source | 161,402,000Source | 198,359,000Source | 133,402,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,501,000Source | 5,667,000Source | 7,853,000Source | 3,624,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,614,000Source | 8,442,000Source | 9,264,000Source | 10,138,000Source |
| Other Assets, NoncurrentUSD | 1,221,000Source | 407,000Source | 146,000Source | 146,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 103,249,000Source | 104,202,000Source | 113,969,000Source | 98,495,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 64,000Source | 62,000Source | 62,000Source | 55,000Source |
| Additional Paid in CapitalUSD | 337,371,000Source | 303,004,000Source | 271,973,000Source | 145,221,000Source |
| Retained Earnings (Accumulated Deficit)USD | -248,992,000Source | -189,990,000Source | -134,247,000Source | -84,720,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 72,000Source | 97,000Source | 163,000Source | -27,000Source |
| Stockholders' Equity Attributable to ParentUSD | 87,332,000Source | 112,892,000Source | 137,938,000Source | 60,529,000Source |
| Liabilities and EquityUSD | 190,581,000Source | 217,094,000Source | 251,907,000Source | 159,024,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 30,635,000Source | 34,925,000Source | 45,033,000Source | 30,245,000Source |
| Operating Lease, Liability, CurrentUSD | 552,000Source | 413,000Source | 1,404,000Source | 339,000Source |
| Accounts Payable, CurrentUSD | 6,726,000Source | 10,522,000Source | 11,835,000Source | 8,668,000Source |
| Operating Lease, Liability, NoncurrentUSD | 13,982,000Source | 15,934,000Source | 15,891,000Source | 15,539,000Source |
| Other Liabilities, NoncurrentUSD | 3,049,000Source | 37,000Source | 37,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,784,000Source | 7,197,000Source | 10,458,000Source | 6,216,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 55,583,000Source | 53,306,000Source | 53,008,000Source | 52,711,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 55,583,000Source | 53,306,000Source | 53,008,000Source | 52,711,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -59,002,000Source | -55,743,000Source | -49,527,000Source | -42,815,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 10,623,000Source | 8,419,000Source | 5,352,000Source | 2,133,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 33,823,000Source | 30,603,000Source | 17,352,000Source | 8,111,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,090,000Source | 5,687,000Source | 9,301,000Source | 11,039,000Source |
| Increase (Decrease) in InventoriesUSD | -3,224,000Source | 10,010,000Source | 9,848,000Source | 8,769,000Source |
| Increase (Decrease) in Accounts PayableUSD | -3,796,000Source | -1,313,000Source | 3,167,000Source | 4,612,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -15,970,000Source | -37,167,000Source | -34,575,000Source | -30,648,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 0Source | 20,000,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 13,251,000Source | 35,375,000Source | -81,299,000Source | -76,518,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 13,517,000Source | 11,593,000Source | 11,458,000Source | 14,838,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 902,000Source | 268,000Source | 13,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,077,000Source | 160,000Source | 109,383,000Source | 20,806,000Source |
| Repayments of Long-term DebtUSD | — | — | 0Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -642,000Source | -1,632,000Source | -6,491,000Source | -86,360,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,708,000Source | 11,350,000Source | 12,982,000Source | 19,473,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,997,000Source | 4,955,000Source | 5,167,000Source | 4,398,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 33,823,000Source | 30,603,000Source | 17,352,000Source | 8,111,000Source |
| Amortization of Debt Issuance CostsUSD | 292,000Source | 298,000Source | 297,000Source | 244,000Source |
| Amortization of Intangible AssetsUSD | 1,000,000Source | 1,000,000Source | 500,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | -2,737,000Source | 0Source | 0Source | -4,483,000Source |
| General and Administrative ExpenseUSD | 62,744,000Source | 55,720,000Source | 47,031,000Source | 32,999,000Source |
| GoodwillUSD | 12,815,000Source | 12,815,000Source | 12,815,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Marketable Securities, Unrealized Gain (Loss)USD | -25,000Source | -66,000Source | 190,000Source | -27,000Source |
| Net Income (Loss) Attributable to ParentUSD | -59,002,000Source | -55,743,000Source | -49,527,000Source | -42,815,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -49,527,000Source | -42,815,000Source |
| Operating ExpensesUSD | 223,906,000Source | 223,952,000Source | 203,365,000Source | 149,159,000Source |
| Other Nonoperating Income (Expense)USD | -4,848,000Source | -55,000Source | 1,901,000Source | -7,971,000Source |
| Other Operating Income (Expense), NetUSD | 432,000Source | 324,000Source | 342,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 546,000Source | 428,000Source | 1,869,000Source | 2,187,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 212,690,000Source | 209,357,000Source | 187,118,000Source | 141,838,000Source |
| Cost of RevenueUSD | 42,938,000Source | 41,093,000Source | 35,181,000Source | 27,523,000Source |
| Operating Income (Loss)USD | -54,154,000Source | -55,688,000Source | -51,428,000Source | -34,844,000Source |
| Other Nonoperating Income (Expense)USD | -4,848,000Source | -55,000Source | 1,901,000Source | -7,971,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -59,002,000Source | -55,743,000Source | -49,527,000Source | -42,815,000Source |
| Earnings Per Share, BasicUSD per share | -0.93Source | -0.9Source | -0.81Source | -0.77Source |
| Earnings Per Share, DilutedUSD per share | -0.93Source | -0.9Source | -0.81Source | -0.77Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 63,269,003Source | 62,112,037Source | 60,852,153Source | 55,276,834Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 63,269,003Source | 62,112,037Source | 60,852,153Source | 55,276,834Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,000,000Source | 1,000,000Source | 500,000Source | — |
| General and Administrative ExpenseUSD | 62,744,000Source | 55,720,000Source | 47,031,000Source | 32,999,000Source |
| Gross ProfitUSD | 169,752,000Source | 168,264,000Source | 151,937,000Source | 114,315,000Source |
| Interest ExpenseUSD | 5,320,000Source | 5,256,000Source | 5,167,000Source | 4,398,000Source |
| Investment Income, NetUSD | 2,777,000Source | 4,877,000Source | 6,726,000Source | 910,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -49,527,000Source | -42,815,000Source |
| Operating ExpensesUSD | 223,906,000Source | 223,952,000Source | 203,365,000Source | 149,159,000Source |
| Other Operating Income (Expense), NetUSD | 432,000Source | 324,000Source | 342,000Source | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | 0Source | 0Source |
| Research and Development ExpenseUSD | 20,282,000Source | 20,589,000Source | 15,440,000Source | 13,584,000Source |
| Selling and Marketing ExpenseUSD | 140,880,000Source | 147,643,000Source | 140,894,000Source | 102,576,000Source |
Filing attachments
tmci-ex99_1.htm · 8-K · 2026-08-07
EX-99.1 2 tmci-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla. - August 7, 2026 - Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights • Generated revenue of $45.4 million in…
Read attachment ↗tmci-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 tmci-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2026 Financial Results PONTE VEDRA, Fla. - May 8, 2026 - Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Generated revenue of $47.2 millio…
Read attachment ↗